Loading
Adding a CD30-directed antibody-drug conjugate to a tablet-and-antibody pairing added about five months of median survival for heavily pretreated people with relapsed aggressive lymphoma.
A randomised, double-blind, placebo-controlled, multicentre phase 3 trial comparing brentuximab vedotin with lenalidomide and rituximab against placebo with lenalidomide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. 230 patients were randomised, 112 to brentuximab vedotin and 118 to placebo; two in the placebo arm did not receive treatment. Brentuximab vedotin or placebo was given every three weeks, lenalidomide daily and rituximab every three weeks. Overall survival was the primary endpoint, with a prespecified interim analysis after 134 deaths against an efficacy boundary of two-sided p = 0.0232.
At a median follow-up of 16.4 months, median overall survival was 13.8 months with brentuximab vedotin against 8.5 months with placebo (hazard ratio 0.63, 95 per cent confidence interval 0.45 to 0.89, two-sided p = 0.009). Median progression-free survival was 4.2 months against 2.6 (hazard ratio 0.53, 0.38 to 0.73).
The evidence behind the United States approval of brentuximab vedotin with lenalidomide and a rituximab product for relapsed or refractory diffuse large B-cell lymphoma after two or more lines in patients not eligible for an autologous transplant or CAR-T. It is also the first demonstration that a CD30-directed conjugate helps in a disease where CD30 expression is variable.
Shares Older and multimorbid patients are excluded and undertreated, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Older and multimorbid patients are excluded and undertreated, Lenalidomide, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL, Older and multimorbid patients are excluded and undertreated, CD20, Rituximab and the tag lymphoma-evidence.
Shares Older and multimorbid patients are excluded and undertreated, Lenalidomide, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Older and multimorbid patients are excluded and undertreated, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Older and multimorbid patients are excluded and undertreated, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Older and multimorbid patients are excluded and undertreated, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Toxicity and quality of life are undervalued and the tag lymphoma-evidence.